Digoxin pharmacokinetics and MDR1 genetic polymorphisms

European Journal of Clinical Pharmacology

Volumn 58, Issue 12, 2003, Pages 809-812

  Verstuyft, Céline ^b   Schwab, Mathias ^c   Schaeffeler, Elke ^c   Kerb, Reinhold ^d   Brinkmann, Ulrich ^d   Jaillon, Patrice ^b   Funck Brentano, Christian ^b   Becquemont, Laurent ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d Epidauros Biotechnologie AG   (Germany)

Author keywords

Digoxin Genetic polymorphism Human; MDR1; P glycoprotein

Indexed keywords

CYTOSINE; DIGOXIN; GLYCOPROTEIN P; GUANINE; THYMINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DISPOSITION; EXON; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; MDR1 GENE; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; URINARY EXCRETION;

EID: 0037955805     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0567-5     Document Type: Article

References (14)

1. Fromm MF, Eichelbaum M (2002) The pharmacogenomics of human P-glycoprotein. In: Licinio J, Wong M-L (eds) Pharmacogenomics: the search for individualized therapies. Wiley-VCH, Weinheim, pp 159-178
2. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473-2378
3. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199
4. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, et al (2002) MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53:526-534
5. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al (2002) Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36
6. Ragueneau I, Poirier JM, Radembino N, Sao AB, Funck-Brentano C, Jaillon P (1999) Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. Br J Clin Pharmacol 48:453-456
7. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, et al (2001) Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 70:311-316
8. Verstuyft C, Strabach S, El Morabet H, Kerb R, Brinkmann U, Dubert I, et al (2003) Dipyridamole enhances digoxin bioavailability via P-glycoprootein inhibition. Clin Pharmacol Ther 73(1):51-60
9. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al (2001) MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18:1400-1404
10. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72:584-594
11. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, et al (2002) Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72:209-219
12. Bhardwaj RK, Gleser H, Becquemont L, Klotz U, Gupta SK, Fromm MF (2002) Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 302:645-650
13. Darbar D, Fromm MF, Dell'Otto S, Kim RB, Kroemer HK, Eichelbaum M, et al (1998) Modulation by dietary salt of verapamil disposition in humans. Circulation 98:2702-2708
14. Dresser G, Bailey D, Leake B, Schwarz U, Dawson P, Freeman D, et al (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11-20